Inez Vincent: I would have to refer to Thomas Arendt's idea of neuronal activity-driven processes that may lead to cell cycle activation. He has suggested that a degree of plasticity (a good thing) might eventually lead to activation of the cell cycle and death (a bad thing).
Ben Wolozin: I would like to throw out a simple hypothesis that might explain much of these phenomena. Intracellular accumulation of Aβ (or tau) leads to proteasomal inhibition. All of the cell cycle-regulated proteins are also controlled via proteasomal degradation. Hence, as proteasomal inhibition increases, the activity of the cell-cycle regulators increase and the neurons go into a state reminiscent of mitosis. Thus, anything that inhibits the protease might cause this.
Inez Vincent: Any idea, Ben, why this might not happen in the transgenic mouse models that produce abundant Aβ?
Ben Wolozin: These animals produce lots of Aβ, but it is extracellular, and the neurons are not damaged until late.
Jan Hallows:
Ben, but what leads to the initial activation of the cell cycle prior to the accumulation of tau or Aβ?
Ben Wolozin: Jan, I think the simplest explanation is that small Aβ oligomers or oxidative stress cause the proteasomal inhibition.
Zsuzsanna Nagy: Ben, how do you explain the cell cycle-related death in neurodegenerative disorders that do not have tau or amyloid accumulation?
Ben Wolozin: Many things cause proteasomal inhibition -oxidative stress, aggregated proteins. Hence, one can get to the same phenotype from many directions.
Karl Herrup: I like the proteasome idea in general, but would this not kill a neuron rapidly?
Mark Smith: I think the inhibition of the proteasome comes secondary to oxidative stress. Zsuzsanna Nagy: I second that, Mark.
Robert Bowser:
Inflammatory responses may also activate cell-cycle kinases.
Zsuzsanna Nagy: Can you elaborate on that, Bob?
Robert Bowser: Inflammation activates signaling pathways that can regulate the activity of kinases involved in cell-cycle regulation.
Inez Vincent: Clearly, proteasome activity is critical for cell-cycle progression.
Douglas Feinstein:
Could there be a relationship among this proteasomal inhibition, chronic NFκB suppression, and the activation of the cell cycle?
Rachael Neve: I think you are on to something there, Douglas.
Perhaps this brings together aspects of inflammatory activation and the role of NFκ in promoting (or inhibiting) cell proliferation?
Ben Wolozin: Douglas, the connection with the proteasome and NFκB is easy, since IκB, which inhibits NFκB, is regulated by the proteasome. However, one could also easily explain NFκB effects independently of the proteasome because there is so much inflammation in AD.
Nathaniel Milton: Ben, is AD not a phenotype arrived at from many directions?
Ben Wolozin: Nathaniel, I am not proposing that proteasomal inhibition causes AD, just the specific hypothesis that proteasomal inhibition could explain changes in cell-cycle proteins.
Ben, I absolutely agree. But there could also be long-term, chronic buildups in some other NFκB-related proteins.
Ben Wolozin: Definitely.
Inez Vincent: Based on the plasticity/neuronal activity idea, it might be toxic metabolites, oxidative damage, DNA damage, or other undetermined factors that may signal this special pathway in selective neurons.
Mark Smith:
We have the classic chicken-and-egg situation: What causes what? We have tried oxidative stress, tau phosphorylation, and proteasome inhibition as initiators, but do not see the appearance of all the other aspects. However, once neurons leave the G 0 phase of the cell cycle, then we see all aspects appearing in a temporal progression.
Craig Atwood: Cell-cycle reentry also could explain the mitochondrial abnormalities (increased mtDNA and COX-1) seen in pyramidal neurons, and hence, oxidative stress. Karl Herrup: Ping, I think the answer is, "not likely", since this would seem to necessitate an early genetic change and would be difficult to explain in terms of the large number of neurons that die.
Inez Vincent: I wonder if it is possible that only certain neurons might be susceptible to using cell cycledriven mechanisms in degeneration -for instance pyramidal neurons -whereas neurons of the substantia nigra, cerebellum, etc., do not?
Gabrielle Strobel: Inez, might that have to do with differences in activity/plasticity? How would you test that?
Inez Vincent: Gabrielle, possibly.
Robert Bowser:
Inez, degenerative selectivity is probably related to plasticity, though cell-cycle activation may only push the neuron towards a more susceptible state, whereby other factors (Aβ, etc.) may then ultimately lead to its demise. Zsuzsanna Nagy: Bob, one wonders whether the neuronal populations that enter the cell cycle depend on personal susceptibility or maybe on the nature of the mitogenic stimulus.
Inez Vincent: Yes, Bob. However, cell-cycle activation is prominent in certain other degenerative disorders, such as Niemann-Pick disease, that totally lack amyloid deposition. Zsuzsanna Nagy: Inez, we found that granule cells with Pick bodies also follow the cell-cycle path.
Craig Atwood: Inez, has not amyloid been shown to deposit with cholesterol in Niemann-Pick disease? Nathaniel Milton: Inez, do not forget the glial cell cycle.
Karl Herrup: Let us not forget that the evidence for this cell-cycle thing goes way back to the beginnings of the CNS. The breadth of applications to neurodegeneration is thus potentially much wider.
Ping Lu: I agree with Inez. It seems that neurons in certain regions are activated, but not others.
Zsuzsanna Nagy: Ping Lu, I think the neurons involved vary from one disease to another. Maybe individual sensitivities will determine which person gets what type of neurodegeneration.
Mark Smith: Inez, do you think that the initiating event is specific for certain neurons or that only pyramidal neurons develop the phenotype?
Gabrielle Strobel: Current transgenic mice in AD (AβPP, presenilin, tau, apoliporprotein E) are all partial models. Have any of them been crossed with transgenic mice used in cell-cycle and cancer research to see if that recapitulates AD more fully?
Mark Smith: Gabrielle, a nice thought, except that cancer involves successful division; this is something else.
Inez Vincent: Yes, Gabrielle, but it is impossible to ignore the selectivity. And here, activity and perhaps other biochemical features may be important, such as the amount of tau. Ping Lu: PIN-1 may be a factor linking cell cycle, AD, and cancer [1] .
Karl Herrup: Ping, perhaps you need to spell out your PIN-1 idea a bit more for those of us who have just heard it here.
Ping Lu: PIN-1 is critical for controlling G 1 /S and mitosis. It is required for dephosphorylation of many epitopes of the MPM-2 antibody. PIN-1 is overexpressed in cancer, but its function is inhibited in AD.
Nathaniel Milton: Mark, is the AD brain we all look at the survival success?
Mark Smith: To some extent, yes, at least those neurons with pathology.
Rachael Neve: I would like to propose that AβPP is intimately involved in this cell-cycle process. We have shown that AβPP interacts with the cell-cycle protein AβPP-BP1, and that activation of AβPP-BP1 can cause neurons to enter the cell cycle [2] . Perhaps as we age, the interaction between AβPP and AβPP-BP1 becomes unregulated. Due to oxidative stress or inflammation, maybe? Just to add to this, we also have evidence that NFκB activation inhibits AβPP-BP1's ability to push neurons into the cell cycle, showing that NFκB is neuroprotective in this process.
Craig Atwood: Rachael, yes, AβPP-BP1 needs to be further explored.
Inez Vincent: Since Ping mentioned "oncogenes" earlier, I wanted to draw everyone's attention to the fact that the cdc2 gene lies in the new AD susceptibility region on chromosome 10! Karl Herrup: Inez, I would love the connection, but cdc2 is pretty late in the cell cycle, no?
June Kinoshita: Inez, that is interesting! Have you talked to any of the geneticists about this? Nathaniel Milton: Gene differences in cdc2 have not been linked to AD yet. We are still searching.
Inez Vincent: Great, Nathaniel! Ping Lu: Plk1 is another oncogene involved in AD [3] .
Karl Herrup: How is it involved?
Ping Lu: Plk1 is amplified and hyperactivated in cancer; it is also known to be activated in AD.
Ken Maiese: To add a little more fuel to the fire, especially with neuronal vulnerability, we have found that attempted cell-cycle regulation impacts both the early (membrane asymmetry) and late stages of neuronal injury (genomic DNA injury).
Rachael Neve: Ken, can you elaborate on that? Have you published it?
Ken Maiese: Yes, see Lin et al. [4] . We have shown that exposure to toxic injuries, such as free radicals, leads to progressive neuronal injury over 24 hours. This is accompanied by the rapid induction of the initial phase of programmed cell death that involves the exposure of membrane phosphatidylserine residues. Using the cell-cycle markers bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA), we have illustrated that the progressive exposure of membrane phosphatidylserine residues occurs in concert with the attempt by postmitotic neurons to enter the cell cycle. This ill-fated attempt occurs only in the same population of neurons that have begun the initial stages of programmed cell death, suggesting that attempted induction of a latent cell cycle in postmitotic neurons correlates with the early stage.
Mark Smith: Far be it from me to defend the amyloidists, but let us remember that neuronal injury/stress of any kind increases AβPP/Aβ, so it might be involved in so-called "non-amyloid" conditions [5] .
Inez Vincent: That is correct, Mark, and brings the presenilins into the fray, as well! Rachael Neve: Mark, to support your statement: A simple increase in AβPP levels causes neurons to enter the cell cycle. We have shown that in our primary neuronal culture model, where overexpression of AβPP by way of HSV vectors causes DNA synthesis.
Inez Vincent: Rachael, do you think that postmitotic neurons would behave differently from primary neurons?
Rachael Neve: Inez, our primary cultures are largely postmitotic.
Karl Herrup: I still think a neuron that is driven into the cycle will die rather than divide. This implies that the specificity (at least to this type of death) must be in the signal, not in the neuron.
Inez Vincent: I agree, Karl.
Ping Lu: So do I; neurons will die if driven to divide. I think this is a major difference between cancer and AD.
Zsuzsanna Nagy: Rachael, did your neurons actually divide, and, if so, what is the time required for cycle completion?
Rachael Neve: Our neurons do not divide; they die after showing DNA synthesis. We have shown that inhibitors of DNA synthesis do not prevent the death, but inhibitors of the G 0 -S phase transition do.
Robert Bowser: Zsuzsanna, the nature of the mitogenic stimulus will define the intracellular pathways activated, and thus, the presence of any cell-cycle proteins activated.
Karl Herrup: Bob, I agree.
Inez Vincent: One thing we must then keep in mind is how this "mitogenic" stimulus is propagated to different neurons and brain regions in AD.
Ken Maiese:
We have found that a small percentage of neurons enter the cell cycle, but do not succumb to injury. Any thoughts?
Robert Bowser: Ken, I think that a neuron's susceptibility will depend on how far into (if at all) the cell cycle it truly progresses.
Karl Herrup: Ken, I think GABAergic neurons are spared this rule. Does anyone else find that GABAergic neurons in (cortical) cultures behave differently with regard to the cycle?
Inez Vincent: That is interesting, Ken and Karl.
Rachael Neve: Is that right, Karl? Do you find that GABAergic neurons are not susceptible to cell-cycle entry?
Karl Herrup: They are susceptible to cell-cycle entry, just not to cycle-induced death.
Rachael Neve: That is very interesting. I assume you have determined that in a primary neuronal culture, using ICC coupled with BrdU labeling?
Karl Herrup: Yes, the results are from culture.
Inez Vincent: This would certainly need to be followed up with other neurotransmitter-specific lines.
Karl Herrup: I have been trying to find out from a number of pathologists whether GABA neurons are known to be specifically spared or targeted in AD. No answers so far. Zsuzsanna Nagy: Karl, I do not think it has been looked at yet.
Ken Maiese: Actually, some believe that those neurons that enter the cell cycle but are not injured represent a "greater plasticity" and may function along the same lines as embryonic stem cells [6] .
Karl Herrup: Ken, I think you are on to something. I wonder if these cells are not the source of the neurospheres that everyone seems to culture out of adult brain.
Karl, that is a possibility. Many questions still exist. We also know that in neuronal models, attempted cell-cycle regulation accounts for approximately 40-50 percent of the neurons injured, so other, more downstream cellular pathways also play a role. 
Rachael Neve: What do you mean by that?
Inez Vincent: In Niemann-Pick disease Type C, we have found that Purkinje neurons contain hyperphosphorylated tau and mitotic proteins. These cells die very early in the disease, but never form NFT. I believe a similar mechanism operates in them and they die, but without forming NFT [7] .
Craig Atwood: Inez, for amyloid in Niemann-Pick Type C cells, see Yamazaki et al. [8] .
Karl Herrup: Inez, have you looked at ataxiatelangiectasia?
Inez Vincent: I would love to look at ATM, but no time! But June, producing a cell-cycle model in brain is going to be difficult, and may have to be approached sort of wildly.
Robert Bowser: June, I have looked at changes in retinoblastoma and E2F1 in AβPP and SOD1 transgenic mice. We have not seen any changes in the AβPP transgenic mice, and little neuronal cell death occurs in these animals. However, we did see changes in the SOD1 mice prior to the onset of motor neuron cell death.
Ken Maiese: Bob, I definitely agree with you. We find, though, that the cells appear to stop prior to G 1 , similar to several other published reports.
June Kinoshita: Bob, just to be clear, you did see cellcycle gene expression in SOD1 mice prior to neuronal degeneration? Robert Bowser: June, yes, prior to and concurrent with mitochondrial vacuolation. We are currently following up these observations and hope to better define the temporal pattern and relationships (if any) to cell death.
Inez Vincent: Some of you may hate me for saying so, but it really is not possible to use neuronal cultures (even if they are "differentiated") as models for cell cycle-mediated degeneration, per se. Primary neurons and neuronal cell lines are sustainable in cell culture primarily because of their cell-cycle abnormalities. It would be far too difficult to interpret results obtained with these cultures in the context of cell cycle-mediated events in mature, differentiated neurons of brain. This does not mean that neuronal cultures are not useful for studying many other aspects of neuronal death, for example, cytoskeletal abnormalities, oxidative damage pathways, and other signaling pathways.
Inez Vincent: My response to June's comment is that we need to launch a serious study of cell-cycle proteins in normal human brain so we better understand the picture in a normal neuron. These proteins have not been previously studied in brain, and so we know nothing about what they might be doing in normal neurons.
June Kinoshita: To elaborate on Ben's simple scenario [mentioned a while back], perhaps a neuron under stress is expressing cell-cycle proteins to carry out some plasticity-related functions, but they build up because Aβ is gumming up the proteasomal system, and reach a level where they drive the neuron into mitosis?
Mark Smith: June, I respectfully disagree with your sequence of events [12] .
Ping Lu:
June, that is a good summary.
Karl Herrup: June, I am not sure I can buy into this one completely. There still needs to be a trigger and a source of specificity. Zsuzsanna Nagy: Gabrielle, there is no definite answer to that one, yet. Are you interested?
Gabrielle Strobel: I will be interested in taking it in 20 years! In the test, are AD and control groups completely separate, or do they overlap somewhat? Zsuzsanna Nagy: There is a small overlap. We are trying to figure that one out. It might have to do with the age-related changes we talked about earlier. To be useful, the test will have to have an age correction, somehow. Zsuzsanna Nagy: Nathaniel, yes, I heard Inez Vincent mention it before. I am looking forward to some reprints.
Inez Vincent: Karl mentioned earlier that it probably does not start with cdc2. At least in the cell cycle, gene expression is often coordinated. Whether this is true of neurons needs to be determined.
June Kinoshita: Zsuzsanna, you mentioned that cellcycle regulators are expressed in epileptic neurons. The mouse models for epilepsy should be pretty good. Has anyone looked at them? Zsuzsanna Nagy: June, I think there were some studies, but I have not followed them closely.
Gabrielle Strobel: A basic question: Neuronal loss in AD starts in the entorhinal cortex and then proceeds in a fairly predictable anatomical pattern. Does the expression of cell-cycle markers match this pattern?
Inez Vincent: We looked at the brains of Huntington's disease victims. Did not find any cell-cycle aberrations. We have unfortunately not had access to the entorhinal region. If someone is willing to send me the tissue, I would love to do that.
Mark Smith:
Gabrielle, the cell cycle precedes, in my opinion.
Gabrielle Strobel: Mark, I understand, but do cellcycle aberrations also proceed through the brain in the anatomical patterns seen for the neurodegeneration? Zsuzsanna Nagy: Gabrielle, I do not know of a systematic study, but in Down's syndrome brains, we find the cell cycle-related protein expression in areas where AD will develop for sure later [14] .
Ken Maiese: Zsuzsanna, that is very interesting. Can you elaborate on the time frame of this? Zsuzsanna Nagy: Ken, Down's patients develop AD when they are about 30-40 years. The cell-cycle markers appear when they are in their teens [14] .
Karl Herrup: Zsuzsanna, is this published? That is a great finding.
Ken Maiese: Zsuzsanna, how do you know that there exists a specific causal relationship? I realize, at this time, this is more of a hypothetical question, but as I mentioned before, we do not find that all cell-cycle induction in neurons leads to injury. Zsuzsanna Nagy: Ken, I think that depending on the age of the rat, you might find differences in neuron behavior and survival after mitogenic stimulation.
Inez Vincent: Zsuzsanna brings up a good point. The duration of the changes make it very difficult to study prospectively.
Zsuzsanna Nagy: What model did you use?
Ken Maiese: We use primary rat neurons.
June Kinoshita: Everyone, this has been very lively and informative. Can you propose some priority research questions to move this whole area of inquiry forward?
Karl Herrup: June, I think what we need are models. Culture or on the hoof. Right now, our mice are letting us down when it comes to neuron death.
Ben Wolozin: I agree with Karl 300 percent (or $100,000 worth of agreement). One cannot study this issue in a causative, hypothesis-driven model unless there is a good animal model that recapitulates the cellular changes in AD. The P301L tau x Aβ model might be the best. Then one can ask what happens if the cell-cycle changes are blocked.
Inez Vincent: I would like to suggest sharing tissues so a variety of different markers may be followed in the same cases and the results more meaningfully interpreted. I wish Steve Snyder were around to make an offer either of organizing this or paying for it.
Mark Smith: Inez, I can help you on this.
Inez Vincent: Awesome, Mark! Nathaniel Milton: If we knock out the cell-cycle inhibitors, do we increase, reduce, or have no effect on neurodegeneration?
Karl Herrup: Nathaniel, good question.
Ping Lu: Some cell-cycle inhibitors have been knocked out. Some sections of brain are bigger (p27).
Inez Vincent: Next step: Let us get together to discuss a more comprehensive model for studying cell-cycle changes in vivo. I have a few ideas and am working on some.
Gabrielle Strobel: As we have reached the end of the hour, I want to thank everyone for participating.
June Kinoshita: Yes, thank you all very much for attending today's chat.
Inez Vincent: June, Gabrielle, and Nico -thanks for taking the initiative in organizing this chat.
